H
Henry Lik‐Yuen Chan
H-index:112
Citation Count:4.9万
Views:0
Biography
No content for now.
Education
No content for now.
Work Experience
No content for now.
Honors & Awards
No content for now.
Is Partial Cure a Realistic Endpoint for Novel Hepatitis B Therapy?
部分治愈是新型乙型肝炎治疗的现实终点吗?
Comparative Risk of Hepatitis B Virus Reactivation in Patients Receiving Immune Checkpoint Inhibitors or Tyrosine Kinase Inhibitors for Liver Cancer
乙型肝炎病毒再激活在肝癌患者中接受免疫检查点抑制剂或酪氨酸激酶抑制剂治疗时的比较风险
Long-Term Dynamic Changes of Alanine Aminotransferase Levels Are Associated With Liver-Related Events in Nucleos(t)ide Analogue-Treated Chronic Hepatitis B Patients in China
中国核苷(酸)类似物治疗的慢性乙型肝炎患者中,丙氨酸氨基转移酶水平的长期动态变化与肝脏相关事件相关。
Association of Metabolic Comorbidities With Fibrosis Severity and Fibrosis Regression in Patients With Chronic Hepatitis B
慢性乙型肝炎患者代谢合并症与肝纤维化严重程度及肝纤维化消退的关系。Clin. Gastroenterol. Hepatol, S1542-3565(25)00411-2
Sequential therapy with antisense oligonucleotide and immune modulator as a strategy for HBV cure
序贯疗法:以反义寡核苷酸和免疫调节剂作为HBV治愈策略
Limited Sustained Remission After Nucleos(t)ide Analog Withdrawal: Results From a Large, Global, Multiethnic Cohort of Patients With Chronic Hepatitis B (RETRACT-B Study)
有限的持续缓解后核苷 (酸) ide类似物退出: 从慢性乙型肝炎患者的大型,全球性,多种族队列的结果 (RETRACT-B研究)
Development and clinical validation of a novel algorithmic score (GAAD) for detecting HCC in prospective cohort studies
在前瞻性队列研究中检测HCC的新型算法评分 (GAAD) 的开发和临床验证

